PT921395E - Ensaio para medicao de fragmentos de proteina em meios biologicos - Google Patents

Ensaio para medicao de fragmentos de proteina em meios biologicos

Info

Publication number
PT921395E
PT921395E PT98309266T PT98309266T PT921395E PT 921395 E PT921395 E PT 921395E PT 98309266 T PT98309266 T PT 98309266T PT 98309266 T PT98309266 T PT 98309266T PT 921395 E PT921395 E PT 921395E
Authority
PT
Portugal
Prior art keywords
protein fragments
medication
assay
biological means
collagen
Prior art date
Application number
PT98309266T
Other languages
English (en)
Inventor
James Thomas Downs
Kimberly Sue Johnson
Peter Steven Mezes
Ivan George Otterness
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT921395E publication Critical patent/PT921395E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT98309266T 1997-11-13 1998-11-12 Ensaio para medicao de fragmentos de proteina em meios biologicos PT921395E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6542397P 1997-11-13 1997-11-13

Publications (1)

Publication Number Publication Date
PT921395E true PT921395E (pt) 2003-06-30

Family

ID=22062616

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98309266T PT921395E (pt) 1997-11-13 1998-11-12 Ensaio para medicao de fragmentos de proteina em meios biologicos

Country Status (10)

Country Link
US (1) US6030792A (pt)
EP (1) EP0921395B1 (pt)
JP (1) JP3258630B2 (pt)
AT (1) ATE237133T1 (pt)
BR (1) BR9804988A (pt)
CA (1) CA2254010A1 (pt)
DE (1) DE69813158T2 (pt)
DK (1) DK0921395T3 (pt)
ES (1) ES2194277T3 (pt)
PT (1) PT921395E (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
PT1149111E (pt) * 1999-01-06 2009-11-19 Univ Southern California Processo e composição para a inibição da angiogénese
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
DE60042487D1 (de) * 1999-07-13 2009-08-13 Univ Southern California Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
WO2002015846A2 (en) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JPWO2002027328A1 (ja) * 2000-09-29 2004-02-05 中外製薬株式会社 抗体分子の構造解析法
EP1409536A2 (en) * 2001-02-12 2004-04-21 Curagen Corporation Human proteins and nucleic acids encoding same
US20030040027A1 (en) * 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
AU2002323540A1 (en) * 2001-08-31 2003-03-18 Pharmacia Corporation Peptide biomarker and method of identification
US20040067882A1 (en) * 2001-10-22 2004-04-08 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20030219843A1 (en) * 2001-12-20 2003-11-27 Welsch Dean J. Methods of diagnosing and treating abnormal growth
US8367013B2 (en) * 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
EP1504033A2 (en) 2002-05-03 2005-02-09 Millenium Biologix Inc. Connective tissue stimulating peptides
AU2003273540A1 (en) * 2002-05-31 2003-12-19 Cognosci, Inc. Assays for measuring matrix metalloproteinase activities
US7285424B2 (en) 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7432105B2 (en) * 2002-08-27 2008-10-07 Kimberly-Clark Worldwide, Inc. Self-calibration system for a magnetic binding assay
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7781172B2 (en) * 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US20040106190A1 (en) * 2002-12-03 2004-06-03 Kimberly-Clark Worldwide, Inc. Flow-through assay devices
US7247500B2 (en) * 2002-12-19 2007-07-24 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
US20040197819A1 (en) * 2003-04-03 2004-10-07 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US7851209B2 (en) 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US7943395B2 (en) * 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7713748B2 (en) * 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US20050112703A1 (en) * 2003-11-21 2005-05-26 Kimberly-Clark Worldwide, Inc. Membrane-based lateral flow assay devices that utilize phosphorescent detection
US20050136550A1 (en) * 2003-12-19 2005-06-23 Kimberly-Clark Worldwide, Inc. Flow control of electrochemical-based assay devices
US7943089B2 (en) * 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
US7521226B2 (en) * 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US20090298196A1 (en) * 2005-01-28 2009-12-03 Uwabe Ken-Ichiro Quantitative measurement method for recombinant protein
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP1996716B1 (en) * 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2209498A2 (en) * 2007-10-03 2010-07-28 Cornell University Treatment of proliferative disorders using antibodies to psma
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
EP2479190A4 (en) * 2009-09-16 2013-12-04 Shionogi & Co ANTIBODY AGAINST A COLLAGEN NEO-EPITOPE
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
DE102012107651A1 (de) * 2012-08-21 2014-02-27 Astrium Gmbh Verfahren zur Durchführung einer biochemischen Analyse, insbesondere im Weltraum
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
AU2019252795A1 (en) * 2018-04-12 2020-10-29 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
CA2148132A1 (en) * 1992-12-04 1994-06-23 Anthony Robin Poole Immunoassay for the measurement of collagen cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
GB9702252D0 (en) * 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay

Also Published As

Publication number Publication date
ES2194277T3 (es) 2003-11-16
EP0921395A3 (en) 1999-09-01
US6030792A (en) 2000-02-29
EP0921395B1 (en) 2003-04-09
DE69813158D1 (de) 2003-05-15
BR9804988A (pt) 2000-03-28
ATE237133T1 (de) 2003-04-15
DE69813158T2 (de) 2003-11-27
JPH11218532A (ja) 1999-08-10
EP0921395A2 (en) 1999-06-09
JP3258630B2 (ja) 2002-02-18
DK0921395T3 (da) 2003-07-07
CA2254010A1 (en) 1999-05-13

Similar Documents

Publication Publication Date Title
PT921395E (pt) Ensaio para medicao de fragmentos de proteina em meios biologicos
DK1025227T3 (da) Humane TOLL-homologer
DE69839444D1 (de) Smad 6 und dessen anwendungen
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
CY1109645T1 (el) Ανθρωπινος πρωτεϊνικος υποδοχεας τυπου toll, σχετικα αντιδραστηρια και μεθοδοι
WO2000020449A3 (en) MODIFIED TGF-β SUPERFAMILY PROTEINS
DE69823985D1 (de) Nachweis der krankheitsbedingten konformation eines proteins
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
ATE440619T1 (de) Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie
ATE246361T1 (de) Verfahren zur bestimmung von ige
BR9810654B8 (pt) mÉtodo de preparaÇço de um polipeptÍdeo, molÉculas de anticorpo e composiÇço.
ES2153671T3 (es) Peptidos neuroactivos.
BR9916325A (pt) Método para expressão de alto nìvel de proteìnas quiméricas de imunoglobulina de receptor de linfotoxina-beta ativas e sua purificação
BR9812783A (pt) "sistemas de detecção para o registro de interações e as relações funcionais de proteìnas"
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
PE20010046A1 (es) Anticuerpos anti-idiotipicos recombinantes
ES2178203T3 (es) Metodos y reactivos para modular la apoptosis.
MX9302488A (es) Proteina humana receptora de glutamato y compuestos de dna relacionados.
DK1169282T3 (da) Sted-specifikke, isotopisk mærkede proteiner og aminosyrer samt biokemiske forstadier hertil
DE60218848D1 (de) Verfahren zur trennung und/oder zum nachweis und/oder zur identifizierung und/oder zur quantifizierung von prionproteinen
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
AU3169599A (en) Method for screening substance promoting oligomerization of receptor protein molecules
DE69836971D1 (de) Methode und apparat zur vorhersage von funktionellen proteindomänen, methode zur verbesserung der proteinfunktion, sowie funktionell verbessertes protein